Identifying Drug-Resistant Bacterial Infections: Opportunity and Activity in the Diagnostics Arena

Decision Resources, Inc, October 2006, Pages: 31

Antibiotic drug resistance is a perpetual and growing source of medical need; however, diagnostics that can identify drug-resistant pathogens are limited in number. As bacteria develop resistance to more agents and classes of antibiotics, the need for rapid diagnostics that can provide diagnostic accuracy and help in patient management (i.e., by helping physicians administer appropriate therapy quickly) will grow urgent. Diagnostics companies should take heed of the significant market opportunity thus presented.

Get the Answers You Need to Shape Your Strategy
Antibiotic drug resistance continues to plague the community and hospital settings. Which setting is more lucrative for the uptake of diagnostics? What features are needed to penetrate these settings?

Currently, most diagnostics identifying drug-resistant pathogens are designed to detect methicillin-resistant Staphylococcus aureus (MRSA). Which pathogens represent future opportunities?

Many diagnostics (e.g., phenotypic tests, molecular tests) are now available to detect pathogens and determine antibiotic susceptibility. Where do future opportunities lie? What challenges must be overcome?

With the availability of better diagnostics for identification of resistant pathogens, treatment practices in the community and the hospital are likely to be impacted. How will the widespread use of diagnostics affect drug development and use of current drugs? Will it increase or decrease use of drugs such as daptomycin, linezolid, and tigecycline?

Scope
- Impact of drug resistance and role of diagnostics: overview of resistance issues in the hospital and community settings and the crucial but limited role diagnostics play.
- Key antibacterial drug-resistant pathogens: overview of key drug-resistant pathogens in the community and hospital settings, and their drug-resistance mechanisms.
- Antibacterial diagnostic technologies: a review of technologies, including phenotypic and molecular tests as well as biological markers.
- Key players: valuable profiles of important companies in the antibacterial diagnostics arena, including information on their current and emerging products.
- Outlook: opportunities and challenges to developing antibacterial diagnostics and the effect of new antibacterial diagnostics on the pharmaceutical industry.

Executive Summary
Strategic Considerations
Stakeholder Implications
Impact of Drug Resistance
Role of Diagnostics in Guiding Treatment
Key Antibacterial Drug-Resistant Pathogens
Staphylococcus
Sites of Infection
Mechanism of Resistance
Enterobacteriaceae
Sites of Infection
Mechanism of Resistance
Streptococcus
Sites of Infection
Mechanism of Resistance
Antibacterial Diagnostic Technologies: Status and Next Steps
Phenotypic Test Technology
Molecular Test Technology
Biological Markers
C-Reactive Protein
Procalcitonin
Other Biomarkers
Select Key Players in Antibacterial Diagnostics
Accelr8 Technology
Acolyte Biomedica
AdvanDx
Becton Dickinson
BioMerieux
Cepheid
HandyLab
Roche
Outlook for Diagnostics
Point-of-Care Testing
Impact of Diagnostics on Drug Development
Remaining Challenges
Bibliography

Tables
1. Mechanisms of Bacterial Resistance to Select Antibiotic Classes of Drugs
2. Key Outcome Parameters of Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus (MRSA and MSSA)
3. Select Existing and Emerging Bacterial Detection and Susceptibility Diagnostic Technologies
4. Select Companies and Their Diagnostic Products
5. Advantages and Disadvantages of Developing Diagnostics for Antibacterial Resistance

Figures
1. Timeline of Discovery of New Classes of Antibiotics
2. Common Pathogens Implicated in Hospital-Acquired Infections
3. Mechanisms of Antibiotic Drug Resistance
4. Mechanisms of Transferring or Spreading Drug Resistance

- Acolyte Biomedica
- AdvanDx
- Axis Shield
- Becton Dickinson
- Binax
- BioMerieux
- Bio-Rad
- Brahms
- Cellestis
- Cepheid
- Chemicon
- Chiron
- Cubist
- Don Whitley Scientific
- GeneOhm Sciences
- Gen-Probe
- Giles Scientific
- HandyLab
- Johnson & Johnson
- King Pharmaceuticals
- Launch
- Mast
- Minerva Biolabs
- Nanogen
- New Horizons Diagnostics
- Nordic Pharma
- Orion Diagnostica
- Pfi zer
- Roche
- Spectral
- Wyeth
- Zonda

Product Samples

A sample for this product is available. Please Login/Register to download this sample.

Customers who bought this item also bought

• Community-Acquired Bacterial Pneumonia (Event Driven)
• Community-Acquired Bacterial Pneumonia
• Hospital-Treated Infections (Event Driven)
• Pipeline Insight: Antibacterials
• Hospital Insight Series: MRSA Infections (Europe)
• Molecular Diagnostics Markets
• Hospital Insight Series: Complicated Skin and Skin Structure Infections (Europe)
• Molecular Diagnostics - Technologies, Markets and Companies
• Methicillin-Resistant Staphylococcus Aureus (Event Driven)
• Automated Microbial Testing Markets